Article
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Antimicrobial agents and chemotherapy - 1 May 2002
Delaugerre Constance, Marcelin Anne-Geneviève, Thibault Vincent, Peytavin Gilles, Bombled Tony, Bochet Marie-Valérie, Katlama Christine, Benhamou Yves, Calvez Vincent
Abstract excerpt
Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.